老年 ALK 重排非小细胞肺癌患者的临床病理特征。
Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.
机构信息
Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan
Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
出版信息
In Vivo. 2020 Jul-Aug;34(4):2001-2007. doi: 10.21873/invivo.11998.
AIM
To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients.
PATIENTS AND METHODS
A retrospective study was performed in 129 ALK rearranged NSCLC patients diagnosed between April 2008 and March 2019 in fifteen Institutions of the Ibaraki prefecture, Japan.
RESULTS
Median age of patients was 63 years. In 59 patients aged 65 and older, the proportions of patients with advanced stage and those treated with ALK-tyrosine kinase inhibitor (TKI) were lower than those younger than 65 years. There was no difference in overall survival (OS) between the two age groups. Among the elderly patients, no difference was observed in OS between the patients aged 65-69 and those aged 70 and older. In 89 patients treated with TKI, no significant differences were observed in the progression-free survival of TKIs and OS between patients aged 65 and older and those younger than 65, respectively.
CONCLUSION
Evaluation of ALK gene status and TKI treatment are desirable even for elderly patients.
目的
阐明老年间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者的临床病理特征。
患者和方法
本研究回顾性分析了 2008 年 4 月至 2019 年 3 月期间日本茨城县 15 家医疗机构诊断的 129 例 ALK 重排 NSCLC 患者。
结果
患者的中位年龄为 63 岁。在 59 例年龄≥65 岁的患者中，晚期患者和接受 ALK 酪氨酸激酶抑制剂（TKI）治疗的患者比例低于年龄<65 岁的患者。两组患者的总生存期（OS）无差异。在老年患者中，65-69 岁和 70 岁及以上患者的 OS 无差异。在 89 例接受 TKI 治疗的患者中，年龄≥65 岁和年龄<65 岁的患者 TKI 无进展生存期和 OS 无显著差异。
结论
即使是老年患者，评估 ALK 基因状态和 TKI 治疗也是可取的。
Zotero 插件